JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that further to its press release dated September 5, 2007, it has commenced shipment of Famciclovir Tablets, 125 mg, 250 mg and 500 mg, AB-rated to Novartis’ herpes treatment Famvir® Tablets. As the first company to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.
